Robeco Institutional Asset Management B.V. continued to hold its stake in shares of Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 588,912 shares of the medical research company’s stock at the end of the second quarter. Amgen comprises approximately 0.7% of Robeco Institutional Asset Management B.V.’s holdings, making the stock its 27th largest position. Robeco Institutional Asset Management B.V.’s holdings in Amgen were worth $89,601,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of the company. Oakworth Capital Inc. increased its stake in shares of Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock worth $111,000 after buying an additional 100 shares during the period. Delta Asset Management LLC TN increased its stake in shares of Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock worth $155,000 after buying an additional 85 shares during the period. Capital Advisors Ltd. LLC increased its stake in shares of Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock worth $164,000 after buying an additional 6 shares during the period. Vigilant Capital Management LLC increased its stake in shares of Amgen by 2.6% in the second quarter. Vigilant Capital Management LLC now owns 1,283 shares of the medical research company’s stock worth $195,000 after buying an additional 33 shares during the period. Finally, Evanson Asset Management LLC acquired a new stake in shares of Amgen during the second quarter worth about $211,000. Institutional investors own 79.15% of the company’s stock.
Amgen Inc. (NASDAQ:AMGN) traded up 0.82% during midday trading on Friday, reaching $166.81. 3,999,620 shares of the company’s stock were exchanged. The stock has a market capitalization of $124.83 billion, a price-to-earnings ratio of 17.07 and a beta of 0.87. Amgen Inc. has a 12-month low of $138.06 and a 12-month high of $176.85. The stock’s 50-day moving average is $171.68 and its 200-day moving average is $161.02.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.74 by $0.10. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The firm had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.58 billion. During the same period last year, the firm earned $2.57 earnings per share. The company’s quarterly revenue was up 5.9% on a year-over-year basis. On average, equities analysts forecast that Amgen Inc. will post $11.36 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Wednesday, August 17th were paid a dividend of $1.00 per share. The ex-dividend date was Monday, August 15th. This represents a $4.00 dividend on an annualized basis and a dividend yield of 2.40%. Amgen’s dividend payout ratio is presently 40.90%.
AMGN has been the topic of a number of research reports. Goldman Sachs Group Inc. restated a “buy” rating and set a $202.00 price target on shares of Amgen in a research report on Wednesday, June 15th. Vetr upgraded Amgen from a “hold” rating to a “buy” rating and set a $159.50 price target on the stock in a research report on Monday, June 13th. Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $166.00 price target on the stock in a research report on Wednesday, June 29th. BMO Capital Markets restated a “buy” rating and set a $186.00 price target on shares of Amgen in a research report on Tuesday, July 12th. Finally, Jefferies Group restated a “buy” rating and set a $187.00 price target on shares of Amgen in a research report on Wednesday, July 13th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Amgen presently has an average rating of “Buy” and an average target price of $185.06.
In other news, VP Annette Louise Such sold 3,000 shares of the stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total transaction of $523,770.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.20% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.